Inovio Pharmaceuticals (INO) Net Cash Flow (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Net Cash Flow of -$18.0 million for Q1 2026, down 333.61% sequentially from $7.7 million in Q4 2025, and up 30.49% YoY from -$13.8 million in Q1 2025.
Inovio Pharmaceuticals (INO) Net Cash Flow (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at -$18.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 30.49% year-over-year to -$18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.6 million (down 167.17% YoY) and the FY2025 annual result came in at -$21.5 million, down 141.85% from the prior year.
- Net Cash Flow slipped to -$18.0 million in Q1 2026 per INO's latest filing, from $7.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $44.1 million in Q4 2024 and troughed at -$33.9 million in Q3 2023.
- A 5-year average of -$2.6 million and a median of -$12.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 1081.83% in 2024, then plunged 592.49% in 2025.
- Over 5 years, Net Cash Flow stood at $24.3 million in 2022, then sank by 118.47% to -$4.5 million in 2023, then surged by 1081.83% to $44.1 million in 2024, then plunged by 82.54% to $7.7 million in 2025, then slumped by 333.61% to -$18.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$18.0 million, $7.7 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Jun 30, 2026 | 5.25 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 12.22 Mn |
| Sep 30, 2025 | 12.22 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Mar 31, 2025 | -25.90 Mn |
| Mar 31, 2025 | -25.90 Mn |
| Dec 31, 2024 | 44.13 Mn |
| Dec 31, 2024 | 44.13 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | 14.79 Mn |
| Jun 30, 2024 | 14.79 Mn |
| Mar 31, 2024 | 5.26 Mn |
| Mar 31, 2024 | 5.26 Mn |